194394412 - 1_36ae7aui - PID 1851201 Hi I am Ted Dixon with your INK Morning Report Preview for October 27th: BioVaxys insiders bet on the haptenization of cancer and covid. We are doing a mini-series this week on the Healthcare sector which may be close to putting in a bottom, at least based on our insider sentiment signals. Today, we head into the traditional biotechnology space and revisit Vancouver-based BioVaxys last featured here March 17th. Although recent insider buying has been primarily through options and other means, the stock ranks high on insider commitment. While the stock is down since our March report, technically, it appears to be back in an uptrend trading above both its 50-day and 200-day moving averages and is attempting to over-take its 20-day. The stock hit a 52-week high of 78 cents in February following the February 10th news that Procare Health, a spin out of a Proctor & Gamble division, would be collaborating with BioVaxys in the development of three key BioVaxys women’s health related vaccines. In particular, the terms of the agreement envision the two parties jointly conducting a Phase I Clinical Study in Spain of BioVaxys BVX- haptenized protein vaccine for late-stage ovarian cancer. The BioVaxys haptenized vaccine platform is based on an approach that teaches a patient's immune system to recognize and target viral or tumor antigens via haptenization. Antigen targets are modified with a hapten chemical to make the intruder more visible to immune system with the objective of stimulating a robust immune response. As we mentioned in our March report, BioVaxys is also working on a COVID-19 vaccine. Although BioVaxys clearly has a lot of work ahead, for risk-tolerant biotechnology investors, the stock may provide an opportunity to bet on haptenization as a way to potentially defeat some big biological foes. That is all for today and thanks for stopping by. Click on the notify button under this video on INK Ultra Money to be notified when we have our next preview available. Members can also find our full report under this video. Finally, don’t forget to follow us on Twitter @inkresearch. Join us again tomorrow as we let the insiders guide us to opportunity this fall. This is not a recommendation to buy or sell securities and nothing in this video or in INK reports should be considered financial advice information is for educational purposes INK employees may hold an interest in any stock mentioned in our videos or in our reports.